Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 2906 • 2019 ACR/ARP Annual Meeting
DMARD-free Remission in Established Rheumatoid Arthritis: 2 Year Results of the TARA Trial
Elise van Mulligen¹, Angelique Weel ², Martijn Kuijper ², Mieke Hazes ¹, Annette van der Helm-van Mil ³ and Pascal de Jong ¹, ¹Erasmus MC, Rotterdam, Netherlands, ²Maasstad Hospital, Rotterdam, Netherlands, ³LUMC, Leiden, Zuid-Holland, Netherlands
Background/Purpose: In rheumatoid arthritis (RA) disease outcomes have improved enormously in the last decades. Due to early initiation of therapy, a treat-to-target approach and a…
Abstract Number: 2823 • 2019 ACR/ARP Annual Meeting
Progression to Inflammatory Arthritis After Screening Autoantibody Positive in a Non-Clinical Setting
Jill Norris¹, Elizabeth Bemis ², Marie Feser ³, M. Kristen Demoruelle ⁴, Jennifer Seifert ⁵, Michael Weisman ⁶, Jane Buckner ⁷, Peter Gregersen ⁸, Ted Mikuls ⁹, James O'Dell ⁹, Richard M. Keating ¹⁰, Kevin Deane ³ and V. Michael Holers ⁵, ¹Colorado School of Public Health, Aurora, ²University of Colorado Denver, School of Public Health, Aurora, CO USA, Aurora, ³University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora, CO, ⁴University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora, ⁵University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Denver, ⁶David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁷Benaroya Research Institute, Seattle, WA, ⁸Feinstein Institutes for Medical Research, Manhasset, NY, ⁹VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha, NE, ¹⁰Scrippshealth, La Jolla
Background/Purpose: Rheumatoid arthritis (RA)-related autoantibodies are typically elevated prior to the onset of seropositive RA. Screening for autoantibody (aAb) positive individuals is a means to…
Abstract Number: 41 • 2019 ACR/ARP Annual Meeting
Liver Dysfunction Associated with Rheumatoid Arthritis: Impact of Obesity and Effects of DMARDs in Hepatic Alterations
Ivan Arias de la Rosa¹, Carmen Torres-Granados ¹, Alejandro Ibañez-Costa ², Maria del Carmen Abalos-Aguilera ², Alejandra Patiño-Trives ², Maria Luque-Tevar ², Carlos Perez-Sanchez ³, Jose Cordoba-Chacon ⁴, Rafaela Ortega ², Jerusalem Calvo-Gutierrez ², Eduardo Collantes-Estevez ¹, Alejandro Escudero ⁵, Chary Lopez-Pedrera ² and Nuria Barbarroja ⁶, ¹University of Cordoba/IMIBIC/Reina Sofia Hospital, Cordoba, Spain, ²IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ³Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, Cordoba, Spain, ⁴Department of Medicine, Section of Endocrinology, Diabetes, and Metabolism, University of Illinois, Chicago, USA, Chicago, IL, ⁵IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ⁶University of Cordoba/IMIBIC/Reina Sofia Hospital and CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain
Background/Purpose: 1) To analyze the impact of rheumatoid arthritis (RA) in the liver function, 2) To evaluate the impact of obesity and the effect of…
Abstract Number: 176 • 2019 ACR/ARP Annual Meeting
The Epidemiology of Rheumatoid Arthritis in the Czech Republic
Jakub Závada¹, Monika Bezděková ², Michal Uher ³ and Jiří Jarkovský ⁴, ¹Institute of Rheumatology, Prague, Prague, Czech Republic, ²Institute of Health Information and Statistics of the Czech Republic, Praha, Hlavni mesto Praha, Czech Republic, ³Institute of Health Information and Statistics of the Czech Republic, and Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic, Brno, Czech Republic, ⁴Institute of Health Information and Statistics of the Czech Republic, and Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic, Praha, Hlavni mesto Praha, Czech Republic
Background/Purpose: To describe the epidemiology of Rheumatoid Arthritis (RA) in the Czech Republic (CZ)Methods: We used the administrative database of the National Registry of Reimbursed…
Abstract Number: 209 • 2019 ACR/ARP Annual Meeting
Joint Overuse in Patients with Rheumatoid Arthritis
Daisuke Kobayashi¹, Sachimi Amao ², Satoshi Ito ³, Kiyoshi Nakazono ³, Hajime Ishikawa ⁴ and Ichiei Narita ¹, ¹Division of Clinical Nephrology and Rheumatology, Niigata University, Niigata, Niigata, Japan, ²Nursing department, Niigata Rheumatic Center, Shibata, Japan, ³Department of Rheumatology, Niigata Rheumatic Center, Shibata, Japan, ⁴Department of Rheumatology, Niigata Rheumatic Center, Shibata, Niigata, Japan
Background/Purpose: The development of drug therapies for rheumatoid arthritis (RA), and control of synovitis has now become easier. However, once patients are relieved of pain,…
Abstract Number: 417 • 2019 ACR/ARP Annual Meeting
Contribution of Pain Relief to Function, Fatigue, and Quality of Life When Inflammation Is Controlled in Patients with Rheumatoid Arthritis
Mart A.F.J. van de Laar¹, Janet Pope ², Yvonne Lee ³, Bruno Fautrel ⁴, Kei Ikeda ⁵, Amanda Quebe ⁶, Xiang Zhang ⁶, Carol Gaich ⁶, Francesco De Leonardis ⁶, Jeffrey Lisse ⁶, Jennifer Workman ⁶, Roy Fleischmann ⁷, Mark Genovese ⁸ and Peter Taylor ⁹, ¹Arthritis Center Twente, Enschede, Netherlands, ²Western University, London, ON, Canada, ³Northwestern University Feinberg School of Medicine, Chicago, ⁴Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France, ⁵Chiba University Hospital, Chiba, Japan, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ⁸Stanford University, Stanford, CA, ⁹University of Oxford, Oxford, United Kingdom
Background/Purpose: Baricitinib, an oral selective Janus kinase 1 and 2 inhibitor, has shown clinical efficacy and patient-reported pain relief in patients (pts) with RA and…
Abstract Number: 459 • 2019 ACR/ARP Annual Meeting
The Effects of Erythrocytes and Platelets on Disease Activity in Patients with RA – ANSWER Longitudinal Cohort Study –
Akira Onishi¹, Kengo Akashi ¹, Sadao Jinno ², Yonsu Son ³, Hideki Amuro ³, Toru Hirano ⁴, Yuichi Maeda ⁵, Motomu Hashimoto ⁶, Wataru Yamamoto ⁶, Kosaku Murakami ⁶, Ryota Hara ⁷, Masanori Katayama ⁸, Tohru Takeuchi ⁹, Takuya Kotani ⁹, Jun Saegusa ¹ and Akio Morinobu ¹, ¹Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ²Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Osaka, Japan, ³First Department of Internal Medicine, Kansai Medical University, Osaka, Japan, ⁴Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Osaka, Japan, ⁵Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Osaka, Japan, ⁶Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁷The Center for Rheumatic Disease, Department of Orthopedic Surgery, Nara Medical University, Nara, Japan, ⁸Department of Rheumatology, Osaka Red Cross Hospital, Osaka, Japan, ⁹Department of Internal Medicine IV, Osaka Medical College, Osaka, Japan
Background/Purpose: Experimental models suggested both erythrocytes and platelets activated immune cells and enhanced inflammation in inflammatory arthritis. Although previous cross-sectional studies showed the form and…
Abstract Number: 497 • 2019 ACR/ARP Annual Meeting
Women with Rheumatoid Arthritis Have Higher Lifetime Occupational and Non-occupational Exposure to Silica Dust Compared to French General Population
Johanna Sigaux¹, Catherine Cavalin ², Odile Macchi ², Salima Challal ³, Mylene Petit ⁴, Patrice Decker ⁵, Emma André ⁴, Paul-André rosental ², Marie-Christophe Boissier ⁶ and Luca Semerano ⁷, ¹INSERM UMR 1125, Université Paris 13, Bobigny, France, ²SILICOSIS project, ERC Advanced Grant, Centre for European Studies, Sciences Po, Paris, France, Paris, France, ³Assistance Publique-Hôpitaux de Paris, Hôpital Avicenne Service de Rhumatologie, Bobigny, France, ⁴INSERM UMR 1125 Sorbonne Paris Cité, Université Paris 13, 93000 Bobigny, France, Paris, France, ⁵Inserm UMR 1125, University of Paris 13, Sorbonne Paris Cité, Bobigny, France, ⁶Assistance Publique-Hôpitaux de Paris (AP-HP), Rheumatology Department, Avicenne Hospital, Bobigny, France, ⁷INSERM UMR 1125 , Université Paris 13, Bobigny, France
Background/Purpose: Occupational exposure to silica dust is a well-known risk factor for ACPA positive rheumatoid arthritis (RA). The role of non-occupational exposure has not been…
Abstract Number: 544 • 2019 ACR/ARP Annual Meeting
Tolerance, Survival, and Adherence to Methotrexate Treatment in Patients with Rheumatoid Arthritis
Juan Sevillano¹, Dafne Capelusnik ², Emilce Schneeberger ³ and Gustavo Citera ⁴, ¹Instituto de Rehablitacion Psicofisica, Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ²Instituto de Rehabilitacion Psicofisica, CABA, Ciudad Autonoma de Buenos Aires, Argentina, ³Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁴Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Background/Purpose: Methotrexate (MTX) is the most frequently used medication in patients with Rheumatoid Arthritis (RA). However, several authors have questioned its success due to the…
Abstract Number: 845 • 2019 ACR/ARP Annual Meeting
Comparison of Rituximab-Associated Hypogammaglobulinemia Rates in Patients with Systemic Rheumatologic Conditions
Stefanie Wade¹ and Vasileios Kyttaris ¹, ¹Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: Rituximab (RTX) is used in a wide variety of rheumatic disease. Emerging guidelines suggest measuring immunoglobulins (Ig) at pre-treatment screening and prior to repeat…
Abstract Number: 978 • 2019 ACR/ARP Annual Meeting
Light Mediated Therapeutics in Arthritis
Victoria Wickenheisser¹, Emily Rabjohns ², Emilia Zywot ³, Natalia Orlova ³, Christina Marvin ³, Song Ding ⁴, David Lawrence ⁴ and Teresa Tarrant ⁵, ¹Duke University School of Medicine, Durham, ²Department of Rheumatology, Duke University Hospital, Durham, NC, ³UNC Department of Chemistry, Chapel Hill, NC, ⁴Division of Medicinal Chemistry and Chemical Biology The UNC Eshelman School of Pharmacy at UNC, Chapel Hill, NC, ⁵Department of Medicine Division of Rheumatology and Immunology, Duke University Hospital, Durham, NC
Background/Purpose: Rheumatoid arthritis (RA) therapies are constrained by the failure to deliver sufficient quantities of drug to the inflamed site, systemic side effects, and the…
Abstract Number: 1179 • 2019 ACR/ARP Annual Meeting
Resting-State Functional Connectivity of Pain Processing Brain Region Associated with Therapeutic Response to Biologics in Rheumatoid Arthritis and Spondyloarthritis
Nobuya Abe¹, Yuichiro Fujieda ¹, Kuniyuki Asou ¹, Kohei Karino ², Michihito Kono ³, Hisashi Narita ⁴, Masaru Kato ¹, Khin Tha ⁵, Kenji Oku ¹, Olga Amengual ¹, Shinsuke Yasuda ¹ and Tatsuya Atsumi ⁶, ¹Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ²Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ³Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan, ⁴Department of Psychiatry, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ⁵Department of Diagnostic and Interventional Radiology, Hokkaido University Hospital, Sapporo, Japan, ⁶Hokkaido University, Sapporo, Japan
Background/Purpose: Background/Purpose: Discriminating inflammatory pain from non-inflammatory pain is critical to determine therapeutic strategy in inflammatory arthritis (IA) such as rheumatoid arthritis (RA) and spondyloarthritis…
Abstract Number: 1346 • 2019 ACR/ARP Annual Meeting
Post-Traumatic Stress Disorder, Depression, Anxiety and Persistence of Methotrexate and TNF Inhibitors in Patients with Rheumatoid Arthritis
Luke Desilet¹, Joshua Baker ², Bryant England ³, Kaleb Michaud ¹, Jennifer Barton ⁴ and Ted Mikuls ⁵, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pennsylvania, Philadelphia, PA, ³VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha, ⁴VA Portland Health Care System & Oregon Health & Science University, Portland, OR, ⁵VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Post-traumatic stress disorder (PTSD) is associated with worse outcomes among U.S. Veterans with rheumatoid arthritis (RA) in addition to reduced medication adherence in other…
Abstract Number: 1374 • 2019 ACR/ARP Annual Meeting
Real-World Evidence: Infections Among RA Patients Switching from First Biologic DMARD to Another Treatment in the US
Robin Dore¹, Jenya Antonova ², Huan Huang ³, Lawrence Chang ², Xin Wang ³ and Mark Genovese ⁴, ¹Private practice, Tustin, CA, ²Gilead Sciences, Foster City, CA, ³IQVIA, Plymouth Meeting, PA, ⁴Stanford University, Stanford, CA
Background/Purpose: Infections are common safety events monitored in RA patients.1 ACR guidelines limit the use of live vaccines in patients who are on biologic (b)DMARDs…
Abstract Number: 1409 • 2019 ACR/ARP Annual Meeting
Comparison of Healthcare Resource Utilization and Costs of Type 2 Diabetes Mellitus (T2DM)-Related Complications in Medicare Beneficiaries with Rheumatoid Arthritis (RA) and T2DM Who Initiated Treatment with Abatacept versus Other Targeted Disease-Modifying Anti-Rheumatic Drugs
Vardhaman Patel¹, Zulkarnain Pulungan ², Anne Shah ², Barton Jones ², Allison Petrilla ², Leticia Ferri ³, Xue Han ³ and Kaleb Michaud ⁴, ¹Bristol-Myers Squibb, New York City, NY, ²Avalere, washington, DC, ³Bristol-Myers Squibb Company, Princeton, NJ, ⁴University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Use of abatacept, a targeted DMARD (tDMARD), in patients with RA has shown to improve whole-body insulin sensitivity and reduce HbA1c levels.1 Comparative evidence…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].